Expanding the Therapeutic Horizon in MASH

Panelists discuss how the therapeutic landscape for MASH is rapidly diversifying beyond GLP-1 receptor agonists. They explore the potential of dual-acting GLP-1/glucagon agents, thyroid hormone receptor (THR-β) agonists, and other novel compounds currently in advanced trials.

They describe how these emerging therapies aim to target multiple metabolic pathways simultaneously—reducing hepatic fat, improving fibrosis, and addressing systemic inflammation. The group underscores the excitement surrounding recent phase 2 and phase 3 results that suggest meaningful disease modification.

Finally, panelists discuss how the approval of these agents will influence payer decisions, formulary design, and access strategy, ensuring innovation is balanced with affordability.